Diet Pills Philippines: What Actually Works

Ranked by what the published trial evidence supports, with monthly out-of-pocket cost alongside it. The two columns disagree completely, which is the central problem in this market and the reason the supplement aisle stays full.

Pen prices cover four weekly doses, so a pen is effectively a month at a steady maintenance dose. Every pen figure was read from a Watsons listing and checked on 26 August 2026. Xenical and metformin figures are calculated from published Watsons Philippines per-unit pricing at ₱51.25 a 120mg orlistat capsule and ₱4.25 a 500mg RiteMed metformin tablet. Trial percentages come from separate trials in different populations and are not head-to-head comparisons.

Semaglutide and tirzepatide changed what the ceiling looks like. In the STEP 1 trial semaglutide 2.4mg averaged roughly 15 percent of body weight over 68 weeks, and in SURMOUNT-1 tirzepatide 15mg averaged roughly 21 percent over 72 weeks. Nothing oral in this market is close to those numbers, and no supplement has ever produced a trial that would be allowed in the same conversation.

In the Philippines, Ozempic and Trulicity and Victoza are registered for diabetes, and using them for weight is off-label. Wegovy and Mounjaro carry the weight-management framing that Ozempic does not. That distinction is worth understanding before a consultation, because a prescriber choosing between them is choosing between labels and prices as much as between molecules. Detail sits in the GLP-1 overview, the Wegovy versus Ozempic comparison and the Zepbound filing.

The catch is cost and supply. Manila Bulletin reported on 13 June 2026 that Philippine Ozempic prices had risen from about ₱6,200 to over ₱8,700 a pen amid shortage, with some counters above ₱11,000. The chain listings agree: on 26 August 2026 the 0.5mg pen was ₱7,650 at Watsons, Rose Pharmacy and Southstar alike, and the 1mg pen ₱8,734. Almost nobody in this country has coverage for weight-management drugs, so those are out-of-pocket numbers, every month, indefinitely. That is the pressure that pushes people down the ranking table toward the categories below, and it is the pressure the grey market feeds on. Full SKU-level pricing sits in the GLP-1 price index.

Side effects are real and mostly gastrointestinal: nausea, reflux, constipation, and for a minority a genuinely unpleasant first few weeks at each dose step. They are covered in the GLP-1 side effect filing. Weight regain after stopping is documented, which makes these chronic therapies rather than courses, and that is the part of the cost people consistently underestimate.

Duromine is phentermine, a stimulant appetite suppressant, registered with FDA Philippines in 15mg and 30mg capsules under registration DR-XY26998 and dispensed on prescription. It is the most searched diet pill in the country by a wide margin, and it is the strongest thing in a capsule that a Philippine doctor can legally write for.

It also does considerably less than the injectables. Phentermine trials run months rather than years and land in the mid single digits as a percentage of starting weight. The appetite effect attenuates with tolerance while the cardiovascular load does not, which is why the product is labelled for short-term use and why courses in practice tend to run around twelve weeks with a review at the end. Dry mouth, insomnia, raised heart rate and raised blood pressure are the common complaints, and uncontrolled hypertension, arrhythmia, hyperthyroidism and MAOI use are among the reasons a prescriber declines.

The awkward fact about Duromine in this market is that nobody publishes what it costs. No Philippine chain pharmacy lists a price online, and MIMS Philippines carries the monograph without a retail figure. The peso amounts that surface in search are asking prices from classified ads and marketplace sellers rather than pharmacy pricing. The full picture, including registration detail and the sourcing problem, is in the Duromine filing.

Orlistat is the only registered oral option in the Philippines that works on absorption rather than on appetite. It inhibits pancreatic lipase so a portion of dietary fat passes through undigested. That mechanism is also its side effect profile, and it is unusually self-enforcing: eat a fatty meal and the consequences are immediate, oily and difficult to ignore. Some clinicians regard that as a behavioural feature. Most patients regard it as the reason they stopped.

At three capsules a day with meals, ₱51.25 a capsule works out to roughly ₱4,600 a month. The effect size in trials is modest, low single digits as a percentage over placebo, and it depends entirely on there being dietary fat to block. On a low-fat diet the drug has little to act on. On a high-fat diet it acts and you find out about it. That is a narrower useful window than the marketing suggests.

Alli is the 60mg over-the-counter strength sold in some other countries and it is not registered here. Anything offered locally under that name sits outside the registered chain. Contrave, the naltrexone and bupropion combination, shows no evidence of Philippine registration either, so a local offer of it is in the same position.

Metformin is registered, cheap and everywhere. RiteMed 500mg is published at ₱4.25 a tablet at Watsons, which is roughly ₱255 a month at two tablets daily. It is a diabetes drug, and any use of it for weight in someone without diabetes is off-label, which should be stated plainly rather than implied.

The effect on weight is small and it is not evenly distributed. It shows up most in people with insulin resistance or polycystic ovary syndrome and least in people without a metabolic reason for it to work. Nobody serious presents it as a weight-loss drug. What it is, in a market where the effective options run from about ₱7,650 to ₱29,900 a month, is a very cheap intervention with a long safety record that a physician may consider for a metabolic reason, with weight as a secondary effect rather than the point.

This is the largest category by shelf space and the smallest by evidence, and it deserves a blunt paragraph. Garcinia cambogia, green coffee bean extract, raspberry ketone, CLA, apple cider vinegar capsules, chitosan, slimming coffees and detox teas have all been studied. The pattern across those literatures is consistent: effects that are small, inconsistent across trials, frequently funded by the seller, and generally shrinking or disappearing entirely once the lowest-quality studies are excluded. That is not the profile of a working drug. It is the profile of noise.

The regulatory framing explains why they can be sold anyway. In the Philippines these are food supplements, not drugs. A food supplement registration confirms that the product may lawfully be sold. It is not an efficacy finding, it does not evaluate weight-loss claims, and Philippine supplement labelling carries the standard line that the product has no approved therapeutic claims. That line is doing more work than most buyers realise.

There is a subset that does produce a visible short-term result, and that subset is the one to be most careful with. Rapid initial loss on a slimming coffee or tea is normally water and bowel content from a laxative or diuretic action, not fat. Where the result is larger than that, the explanation is sometimes an undeclared pharmaceutical ingredient, which is precisely what the FDA Philippines advisories in the next section describe.

FDA Philippines publishes public health warnings against specific unregistered slimming products by brand name, continuously, at fda.gov.ph. The list is long, it is current, and it is the single most useful free tool in this category. Almost nobody writing affiliate content about Philippine diet pills mentions it exists.

Read those rows carefully and two patterns appear. Most advisories are for being unregistered, meaning FDA has not evaluated the product at all and nobody can say what is in it. A smaller group, of which the SAUSANDO advisory is an example, is issued because drug products were found in something sold as a supplement. That second category is the dangerous one, because a buyer taking what they believe is a herbal capsule has no way to account for an undeclared pharmaceutical in their own medication list.

Three channels serve this market. Pharmacies, which carry the registered prescription products and can be asked for a price. Retail and online marketplaces, which carry the supplement category and a quantity of unregistered product. And private sellers on classifieds and social media, who carry prescription drugs they are not permitted to sell and whatever else finds a buyer.

The third channel is where the harm concentrates, and Philippine enforcement has been visibly active in it during 2026. On 13 May 2026 the NBI arrested two people in Tondo, Manila for selling unregistered tirzepatide online, seizing about ₱310,000 in product, with the case built on RA 9711 section 10(j) together with RA 10175 and RA 7394. On 27 May 2026 the NBI and FDA raided a Pasig aesthetic clinic over unregistered whitening and slimming injectables. The direction of travel is clear enough to plan around.

For the injectable side of this market the counterfeit problem is its own subject, covered in the fake Ozempic filing, alongside the slimming injections filing and the note on Mercury Drug semaglutide stock. The regulatory boundary between registered medicines and research compounds is set out in the legality filing.